April 3, 2012
Study Examines Immunotherapy And Cerebrospinal Fluid Biomarkers In Patients With Alzheimer’s Disease
Immunotherapy with the antibody bapineuzumab in patients with mild to moderate Alzheimer disease resulted in decreases in a cerebrospinal fluid biomarker, which may indicate downstream effects on the degenerative process, according to a report published Online First by Archives of Neurology, a JAMA Network publication.
Alzheimer disease (AD) is a progressive neurodegenerative disease characterized by, among other things, deposits of extracellular β-amyloid (Îβ) plaques and intraneuronal neurofibrillary tangles with accompanying decreases in cerebrospinal fluid (CSF) Îβ and increases in CSF tau proteins. Bapineuzumab is an anti-Îβ monoclonal antibody, and immunotherapy with antibodies against Îβ is one of the major disease-modifying therapeutic approaches being evaluated for AD, the authors write in their study background.
"The reduction in the downstream biomarker CSF P-tau following treatment with bapineuzumab suggests that bapineuzumab reduces brain levels of P-tau, which may also reduce the formation of tangles in the brain," the authors note.
Although there was a reduction in CSF T-tau, it did not reach statistical significance compared with placebo. No clear-cut differences were observed for CSF Îβ, the study results indicate. But the observed decrease in both P-tau and T-tau require further examination, the authors note.
"An important question remains whether such changes in CSF biomarkers correlate with clinical benefit. This question will be addressed in the ongoing bapineuzumab phase 3 trials," the authors conclude.
On the Net: